Loading…

β‑Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design

The discovery of β-lactam (BL) antibiotics in the early 20th century represented a remarkable advancement in human medicine, allowing for the widespread treatment of infectious diseases that had plagued humanity throughout history. Yet, this triumph was followed closely by the emergence of β-lactama...

Full description

Saved in:
Bibliographic Details
Published in:ACS infectious diseases 2022-10, Vol.8 (10), p.1992-2018
Main Authors: Cole, Malcolm S., Hegde, Pooja V., Aldrich, Courtney C.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a345t-e3467e9c9253d695b20ed4942e599703c4c68fa790b18d93bbdd7f8dbc6f87453
cites cdi_FETCH-LOGICAL-a345t-e3467e9c9253d695b20ed4942e599703c4c68fa790b18d93bbdd7f8dbc6f87453
container_end_page 2018
container_issue 10
container_start_page 1992
container_title ACS infectious diseases
container_volume 8
creator Cole, Malcolm S.
Hegde, Pooja V.
Aldrich, Courtney C.
description The discovery of β-lactam (BL) antibiotics in the early 20th century represented a remarkable advancement in human medicine, allowing for the widespread treatment of infectious diseases that had plagued humanity throughout history. Yet, this triumph was followed closely by the emergence of β-lactamase (BLase), a bacterial weapon to destroy BLs. BLase production is a primary mechanism of resistance to BL antibiotics, and the spread of new homologues with expanded hydrolytic activity represents a pressing threat to global health. Nonetheless, researchers have developed strategies that take advantage of this defense mechanism, exploiting BLase activity in the creation of probes, diagnostic tools, and even novel antibiotics selective for resistant organisms. Early discoveries in the 1960s and 1970s demonstrating that certain BLs expel a leaving group upon BLase cleavage have spawned an entire field dedicated to employing this selective release mechanism, termed BLase-mediated fragmentation. Chemical probes have been developed for imaging and studying BLase-expressing organisms in the laboratory and diagnosing BL-resistant infections in the clinic. Perhaps most promising, new antibiotics have been developed that use BLase-mediated fragmentation to selectively release cytotoxic chemical “warheads” at the site of infection, reducing off-target effects and allowing for the repurposing of putative antibiotics against resistant organisms. This Review will provide some historical background to the emergence of this field and highlight some exciting recent reports that demonstrate the promise of this unique release mechanism.
doi_str_mv 10.1021/acsinfecdis.2c00315
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2709020397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2709020397</sourcerecordid><originalsourceid>FETCH-LOGICAL-a345t-e3467e9c9253d695b20ed4942e599703c4c68fa790b18d93bbdd7f8dbc6f87453</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi1ERau2T4CEcuTQtI7txDG3VUtppa2KEJyjiT2JXG2cxeOt1BsHXoBX6YP0IXgSDLugnjjNaPT9_2jmZ-x1xU8rLqozsOTDgNZ5OhWWc1nVL9iBkFqWrRD65bN-nx0T3XHOK9nWStWv2L5suGobIQ_Y96fHn99-LMEmmICwvEHnIaErLiOME4YEyc_hXXHlKc3RW1gVHzHSGm3y90gFBFd8QpvBYuHuIdg886G48DCGmZK3dFJcTzD6MJ78gRch-T6vw-iz1wWSH8MR2xtgRXi8q4fsy-X7z-dX5fL2w_X5YlmCVHUqUapGo7FG1NI1pu4FR6eMElgbo7m0yjbtANrwvmqdkX3vnB5a19tmaLWq5SF7u_Vdx_nrBil1kyeLqxUEnDfUCc0NF1wanVG5RW2ciSIO3Tr6CeJDV_HudwLdswS6XQJZ9Wa3YNNP6P5p_v47A2dbIKu7u3kTQ773v5a_AF_5l84</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2709020397</pqid></control><display><type>article</type><title>β‑Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Cole, Malcolm S. ; Hegde, Pooja V. ; Aldrich, Courtney C.</creator><creatorcontrib>Cole, Malcolm S. ; Hegde, Pooja V. ; Aldrich, Courtney C.</creatorcontrib><description>The discovery of β-lactam (BL) antibiotics in the early 20th century represented a remarkable advancement in human medicine, allowing for the widespread treatment of infectious diseases that had plagued humanity throughout history. Yet, this triumph was followed closely by the emergence of β-lactamase (BLase), a bacterial weapon to destroy BLs. BLase production is a primary mechanism of resistance to BL antibiotics, and the spread of new homologues with expanded hydrolytic activity represents a pressing threat to global health. Nonetheless, researchers have developed strategies that take advantage of this defense mechanism, exploiting BLase activity in the creation of probes, diagnostic tools, and even novel antibiotics selective for resistant organisms. Early discoveries in the 1960s and 1970s demonstrating that certain BLs expel a leaving group upon BLase cleavage have spawned an entire field dedicated to employing this selective release mechanism, termed BLase-mediated fragmentation. Chemical probes have been developed for imaging and studying BLase-expressing organisms in the laboratory and diagnosing BL-resistant infections in the clinic. Perhaps most promising, new antibiotics have been developed that use BLase-mediated fragmentation to selectively release cytotoxic chemical “warheads” at the site of infection, reducing off-target effects and allowing for the repurposing of putative antibiotics against resistant organisms. This Review will provide some historical background to the emergence of this field and highlight some exciting recent reports that demonstrate the promise of this unique release mechanism.</description><identifier>ISSN: 2373-8227</identifier><identifier>EISSN: 2373-8227</identifier><identifier>DOI: 10.1021/acsinfecdis.2c00315</identifier><identifier>PMID: 36048623</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Anti-Bacterial Agents - chemistry ; beta-Lactamases - chemistry ; Humans ; Monobactams</subject><ispartof>ACS infectious diseases, 2022-10, Vol.8 (10), p.1992-2018</ispartof><rights>2022 American Chemical Society</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a345t-e3467e9c9253d695b20ed4942e599703c4c68fa790b18d93bbdd7f8dbc6f87453</citedby><cites>FETCH-LOGICAL-a345t-e3467e9c9253d695b20ed4942e599703c4c68fa790b18d93bbdd7f8dbc6f87453</cites><orcidid>0000-0001-9261-594X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36048623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cole, Malcolm S.</creatorcontrib><creatorcontrib>Hegde, Pooja V.</creatorcontrib><creatorcontrib>Aldrich, Courtney C.</creatorcontrib><title>β‑Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design</title><title>ACS infectious diseases</title><addtitle>ACS Infect. Dis</addtitle><description>The discovery of β-lactam (BL) antibiotics in the early 20th century represented a remarkable advancement in human medicine, allowing for the widespread treatment of infectious diseases that had plagued humanity throughout history. Yet, this triumph was followed closely by the emergence of β-lactamase (BLase), a bacterial weapon to destroy BLs. BLase production is a primary mechanism of resistance to BL antibiotics, and the spread of new homologues with expanded hydrolytic activity represents a pressing threat to global health. Nonetheless, researchers have developed strategies that take advantage of this defense mechanism, exploiting BLase activity in the creation of probes, diagnostic tools, and even novel antibiotics selective for resistant organisms. Early discoveries in the 1960s and 1970s demonstrating that certain BLs expel a leaving group upon BLase cleavage have spawned an entire field dedicated to employing this selective release mechanism, termed BLase-mediated fragmentation. Chemical probes have been developed for imaging and studying BLase-expressing organisms in the laboratory and diagnosing BL-resistant infections in the clinic. Perhaps most promising, new antibiotics have been developed that use BLase-mediated fragmentation to selectively release cytotoxic chemical “warheads” at the site of infection, reducing off-target effects and allowing for the repurposing of putative antibiotics against resistant organisms. This Review will provide some historical background to the emergence of this field and highlight some exciting recent reports that demonstrate the promise of this unique release mechanism.</description><subject>Anti-Bacterial Agents - chemistry</subject><subject>beta-Lactamases - chemistry</subject><subject>Humans</subject><subject>Monobactams</subject><issn>2373-8227</issn><issn>2373-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAQhi1ERau2T4CEcuTQtI7txDG3VUtppa2KEJyjiT2JXG2cxeOt1BsHXoBX6YP0IXgSDLugnjjNaPT9_2jmZ-x1xU8rLqozsOTDgNZ5OhWWc1nVL9iBkFqWrRD65bN-nx0T3XHOK9nWStWv2L5suGobIQ_Y96fHn99-LMEmmICwvEHnIaErLiOME4YEyc_hXXHlKc3RW1gVHzHSGm3y90gFBFd8QpvBYuHuIdg886G48DCGmZK3dFJcTzD6MJ78gRch-T6vw-iz1wWSH8MR2xtgRXi8q4fsy-X7z-dX5fL2w_X5YlmCVHUqUapGo7FG1NI1pu4FR6eMElgbo7m0yjbtANrwvmqdkX3vnB5a19tmaLWq5SF7u_Vdx_nrBil1kyeLqxUEnDfUCc0NF1wanVG5RW2ciSIO3Tr6CeJDV_HudwLdswS6XQJZ9Wa3YNNP6P5p_v47A2dbIKu7u3kTQ773v5a_AF_5l84</recordid><startdate>20221014</startdate><enddate>20221014</enddate><creator>Cole, Malcolm S.</creator><creator>Hegde, Pooja V.</creator><creator>Aldrich, Courtney C.</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9261-594X</orcidid></search><sort><creationdate>20221014</creationdate><title>β‑Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design</title><author>Cole, Malcolm S. ; Hegde, Pooja V. ; Aldrich, Courtney C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a345t-e3467e9c9253d695b20ed4942e599703c4c68fa790b18d93bbdd7f8dbc6f87453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anti-Bacterial Agents - chemistry</topic><topic>beta-Lactamases - chemistry</topic><topic>Humans</topic><topic>Monobactams</topic><toplevel>online_resources</toplevel><creatorcontrib>Cole, Malcolm S.</creatorcontrib><creatorcontrib>Hegde, Pooja V.</creatorcontrib><creatorcontrib>Aldrich, Courtney C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>ACS infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cole, Malcolm S.</au><au>Hegde, Pooja V.</au><au>Aldrich, Courtney C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>β‑Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design</atitle><jtitle>ACS infectious diseases</jtitle><addtitle>ACS Infect. Dis</addtitle><date>2022-10-14</date><risdate>2022</risdate><volume>8</volume><issue>10</issue><spage>1992</spage><epage>2018</epage><pages>1992-2018</pages><issn>2373-8227</issn><eissn>2373-8227</eissn><abstract>The discovery of β-lactam (BL) antibiotics in the early 20th century represented a remarkable advancement in human medicine, allowing for the widespread treatment of infectious diseases that had plagued humanity throughout history. Yet, this triumph was followed closely by the emergence of β-lactamase (BLase), a bacterial weapon to destroy BLs. BLase production is a primary mechanism of resistance to BL antibiotics, and the spread of new homologues with expanded hydrolytic activity represents a pressing threat to global health. Nonetheless, researchers have developed strategies that take advantage of this defense mechanism, exploiting BLase activity in the creation of probes, diagnostic tools, and even novel antibiotics selective for resistant organisms. Early discoveries in the 1960s and 1970s demonstrating that certain BLs expel a leaving group upon BLase cleavage have spawned an entire field dedicated to employing this selective release mechanism, termed BLase-mediated fragmentation. Chemical probes have been developed for imaging and studying BLase-expressing organisms in the laboratory and diagnosing BL-resistant infections in the clinic. Perhaps most promising, new antibiotics have been developed that use BLase-mediated fragmentation to selectively release cytotoxic chemical “warheads” at the site of infection, reducing off-target effects and allowing for the repurposing of putative antibiotics against resistant organisms. This Review will provide some historical background to the emergence of this field and highlight some exciting recent reports that demonstrate the promise of this unique release mechanism.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>36048623</pmid><doi>10.1021/acsinfecdis.2c00315</doi><tpages>27</tpages><orcidid>https://orcid.org/0000-0001-9261-594X</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2373-8227
ispartof ACS infectious diseases, 2022-10, Vol.8 (10), p.1992-2018
issn 2373-8227
2373-8227
language eng
recordid cdi_proquest_miscellaneous_2709020397
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Anti-Bacterial Agents - chemistry
beta-Lactamases - chemistry
Humans
Monobactams
title β‑Lactamase-Mediated Fragmentation: Historical Perspectives and Recent Advances in Diagnostics, Imaging, and Antibacterial Design
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T00%3A44%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%CE%B2%E2%80%91Lactamase-Mediated%20Fragmentation:%20Historical%20Perspectives%20and%20Recent%20Advances%20in%20Diagnostics,%20Imaging,%20and%20Antibacterial%20Design&rft.jtitle=ACS%20infectious%20diseases&rft.au=Cole,%20Malcolm%20S.&rft.date=2022-10-14&rft.volume=8&rft.issue=10&rft.spage=1992&rft.epage=2018&rft.pages=1992-2018&rft.issn=2373-8227&rft.eissn=2373-8227&rft_id=info:doi/10.1021/acsinfecdis.2c00315&rft_dat=%3Cproquest_cross%3E2709020397%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a345t-e3467e9c9253d695b20ed4942e599703c4c68fa790b18d93bbdd7f8dbc6f87453%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2709020397&rft_id=info:pmid/36048623&rfr_iscdi=true